Serina can sell up to $13,270,500 of stock through JonesTrading, which earns up to a 3.0% commission. Its auditor has raised going concern doubt, its lead drug is still preclinical, and the program's size is capped by an SEC float rule.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $23.0 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Serina Therapeutics
Has Serina Therapeutics issued a going-concern warning?
Our latest story on this, dated Apr 28, 2025: "Serina Therapeutics sets up $13,270,500 at-the-market share sales program". The story links the filing or release it is based on. Read the story.
Has Serina Therapeutics raised money recently?
Our latest story on this, dated Apr 28, 2025: "Serina Therapeutics sets up $13,270,500 at-the-market share sales program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Serina Therapeutics?
Serina Therapeutics, Inc. trades under the ticker SER on AMEX.
Where is Serina Therapeutics listed?
Serina Therapeutics, Inc. is listed on AMEX.
What is the SEC CIK of Serina Therapeutics?
The SEC Central Index Key (CIK) for Serina Therapeutics, Inc. is 1708599. Its filings are on SEC EDGAR.
How many shares does Serina Therapeutics have outstanding?
25,400,473 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Serina Therapeutics listed under?
Our directory records Serina Therapeutics, Inc. under United States.
What does Serina Therapeutics do?
Our directory classifies Serina Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Serina Therapeutics?
The ISIN recorded for Serina Therapeutics, Inc. is US81751A1088.
Does aibio.space cover Serina Therapeutics?
aibio.space lists Serina Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Serina Therapeutics incorporated?
SEC records list its state or country of incorporation as AL.
What was Serina Therapeutics's revenue last year?
$130,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Serina Therapeutics profitable?
Serina Therapeutics, Inc. reported a net loss of $19.2 million for the fiscal year ended Dec 31, 2025, and used $18.0 million of cash in operations, per its annual report to the SEC.
How much does Serina Therapeutics spend on research and development?
$13.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Serina Therapeutics have?
$23.0 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Serina Therapeutics
Members talk about Serina Therapeutics (SER). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Serina Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,5.03,7.01,9.01). Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,9.01). Source
Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open AMEX:SER on TradingView.
SEC filings and registration
SEC name
Serina Therapeutics, Inc.
CIK
1708599
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
SER (NYSE)
State or country of incorporation
AL
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
601 GENOME WAY, HUNTSVILLE, AL, 35806
Phone
(256) 327-9630
Shares outstanding
25,400,473 as of 2026-08-10 (10-Q filed 2026-08-13)
Former names
AgeX Therapeutics, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Serina Therapeutics, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker SER, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio